GrayBug to Present at the 6th Annual Conference of the Arnold and Mabel Beckman Initiative for Macular Research


January 9, 2014 – GrayBug is pleased to announce that it has been invited to present at the 6th Annual conference of the Arnold and Mabel Beckman Initiative for Macular Research (BIMR) at the Beckman Center of the National Academies of Science and Engineering on January 23-25, 2014, in Irvine, CA.

About the BIMR

Through a generous grant from the Arnold and Mabel Beckman Foundation, the Beckman Initiative for Macular Research (BIMR) brings together outstanding scientists, engineers, medical researchers, and clinicians — all focused on a common goal: developing a better understanding of atrophic macular degeneration.

Related News

Press release

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

Redwood City, CA – August 20, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), Read more…

Press release

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

Redwood City, CA – February 5, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative therapies for ocular diseases, today announced that the Board of Directors has appointed Frédéric Guerard as Read more…

Press release

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019

ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) • Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF Read more…